Thoracic Oncology Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
J Natl Compr Canc Netw. 2010 Jul;8(7):822-32. doi: 10.6004/jnccn.2010.0059.
Lung cancer is the leading cause of cancer-related mortality in the United States. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Most patients with NSCLC present with locoregionally advanced or metastatic disease, for which response rates and median overall survival remain poor. Platinum-based chemotherapy is the mainstay of treatment for NSCLC in both adjuvant and metastatic disease. Personalized chemotherapy and targeted biologic therapy based on a tumor's histologic and molecular profile have already shown promise in optimizing efficacy. Various markers are currently being investigated for their ability to guide treatment decision-making and management. This article describes these predictive and prognostic markers and details their current role, benefit, and potential future use in the management of patients with NSCLC.
肺癌是美国癌症相关死亡的主要原因。非小细胞肺癌（NSCLC）约占所有肺癌的 85%。大多数 NSCLC 患者表现为局部晚期或转移性疾病，其缓解率和中位总生存期仍然较差。含铂化疗是 NSCLC 辅助和转移性疾病的主要治疗方法。基于肿瘤的组织学和分子特征的个体化化疗和靶向生物治疗已经显示出优化疗效的潜力。目前正在研究各种标志物，以评估其指导治疗决策和管理的能力。本文描述了这些预测和预后标志物，并详细介绍了它们目前在 NSCLC 患者管理中的作用、益处和潜在的未来用途。
